Regenerative Medicine Market (2025-2032)
The Regenerative Medicine Market was valued at $9.52 billion in 2024. This market is expected to reach $45.66 billion by 2032 from an estimated $11.33 billion in 2025, at a CAGR of 22.0% during the forecast period from 2025 to 2032. Regenerative Medicine Market Size & Forecast This market's growth
- Published
- Jun 2025
- Pages
- 240
- Format
- PDF + Excel
- Report ID
- MRHC - 1041181
- Base year
- 2024
- 2024 · BASELINE
- $9.52B
- 2032
- $45.66B
- CAGR 2025–2032
- 22.0%
2024 baseline · 2025–2032 forecast at 22.0% CAGR · hover a bar for the value
Key highlights
By Product: In 2024, the Cell Therapies Segment to Dominate the Regenerative Medicine Market
By Application: In 2024, the Musculoskeletal Segment to Dominate the Regenerative Medicine Market
By End User: In 2024, the Hospital & Clinics Segment to Dominate the Regenerative Medicine Market
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 240 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 22% |
| Estimated Market Size (Value) | $45.66 billion by 2032 |
| Segments Covered | By Product · Gene Therapy · Cell Therapy · Stem Cell Therapy · Autologous Therapy · Allogenic Therapy · Platelet Rich Plasma Therapy · Cell-based Immunotherapy · Tissue Engineering Products · By Application · Cardiology · Ophthalmology · Oncology · Neurology · Immunology & Inflammation · Musculoskeletal · Dermatology · Other Applications · (Note: Other applications majorly include wound care, orthopedics, and sports injuries.) · By End User · Hospitals & Clinics · Ambulatory Surgical Centers |
| Countries Covered | North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Netherlands, Sweden, Switzerland, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa |
| Key Companies | Novartis AG (Switzerland), Biogen Inc. (U.S.), Kite Pharma, Inc. (U.S.), Spark Therapeutics, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Sarepta Therapeutics, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (U.S.), CORESTEMCHEMON Inc. (South Korea), Smith & Nephew plc (England), Vertex Pharmaceuticals Incorporated (U.S.), CSL Behring, LLC (U.S.), Janssen Global Services, LLC (U.S.), Medtronic plc (Ireland), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Ferring Pharmaceuticals A/S (Sweden), Pfizer Inc. (U.S.), bluebird bio Inc. (U.S.), and Vericel Corporation (U.S.). |
Report overview
Segments covered: product, gene therapy, cell therapy, stem cell therapy, autologous therapy, allogenic therapy, platelet rich plasma therapy, cell-based immunotherapy, tissue engineering product, application, cardiology, ophthalmology, oncology, neurology, immunology & inflammation, musculoskeletal, dermatology, other application, end user, hospitals & clinic, ambulatory surgical center. Regions: North America, Europe, Asia-Pacific, Latin America.
This market's growth is driven by factors such as increasing approvals for regenerative medicine, advancements in regenerative medicine, the rising incidence of chronic health conditions, increasing therapeutic applications of regenerative medicine, and increasing R&D funding in regenerative medicine.
Furthermore, the increasing demand for personalized medicine, the growing need for healthy organs for transplant, and the growing number of drugs in the pipeline are expected to create market growth opportunities.
Report infographic
Market dynamics
5 factors across 3 forcesIncreasing Approval for Regenerative Medicine
Regenerative medicine harnesses the body’s inherent healing capabilities to restore, repair, or cultivate damaged or diseased tissues. The regenerative medicine field has witnessed a surge in interest in recent years, driven by its promising applications in oncology, cardiology, neurology, and other medical domains. With the increasing application areas of regenerative medicine, regulatory bodies are approving the use of regenerative medicine for treating different diseases. Some instances of such approvals are as follows:
- In December 2023, Vertex Pharmaceuticals Incorporated (U.S.) received approval from the U.S. FDA for CASGEVY, a cell-based gene therapy designed for the treatment of sickle cell disease (SCD) in patients aged 12 years and older.
- In April 2023, Gamida Cell Ltd. (U.S.) received the U.S. FDA for Omisirge (omidubicel-only), an allogeneic cell therapy indicated for use in patients aged 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning. The therapy aims to reduce the time to neutrophil recovery and the incidence of infection.
Increasing Incidence of Neurodegenerative Disorders
Regenerative medicine is proving to be an effective therapy for various medical conditions, including cardiovascular diseases, ophthalmic diseases, oncology, neurological diseases, immunology & inflammation, musculoskeletal diseases, and dermatological diseases. The growing incidence of these target diseases is a key driver for market growth.
Neurodegenerative disorders, characterized by neuron loss, represent a significant portion of these conditions. Major neurodegenerative disorders include Alzheimer's disease and other memory disorders, Parkinson's disease, Ataxia, and Huntington's disease.
According to the Alzheimer's Association (U.S.), the number of people living with Alzheimer's disease is expected to reach 13 million by 2050 from 6.9 million in 2024 in the U.S. The care cost for people living with dementia is estimated to reach about $1 trillion in 2050 in the U.S. To reduce the high prevalence and cost associated with the disease, healthcare providers are focusing on the use of stem cell therapy for therapeutic purposes. For instance, in April 2024, Regeneration Biomedical (U.S.) started the human clinical trial for RB-ADSC, an autologous stem cell treatment for people living with mild-to-moderate Alzheimer’s disease.
Table of contents
11 chapters · 133 sections · 240 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Product | Cell Therapies | — |
| By Application | Musculoskeletal | — |
| By End User | Hospital & Clinics | — |
By Product
- The Cell Therapies Segment to Dominate the Regenerative Medicine Market
- The cell therapy segment is expected to account for the largest share of 51.2% of the regenerative medicine market.
- This segment is projected to reach $23, 234.7 million by 2031 from an estimated $4,870.8 million in 2024, at a CAGR of 25.0% during the forecast period.
- This segment’s large market share is attributed to the expanding use of cell therapies in treating various conditions such as cancer, autoimmune diseases, cardiovascular ailments, and other chronic illnesses.
- The rising prevalence of long-term conditions has led to a surge in the adoption of cell therapies.
- According to the Centers for Disease Control and Prevention, 6 out of 10 adults in the U.S. have at least one chronic condition, with 4 in 10 adults affected by two or more.
- In cell therapy, damaged tissue is replaced with healthy counterparts or by stimulating tissue repair and regeneration.
- The segment's growth is further propelled by increased approvals for cell therapy and a growing body of positive clinical outcomes associated with regenerative cells.
By Application
- The Musculoskeletal Segment to Dominate the Regenerative Medicine Market
- The musculoskeletal segment is expected to account for the largest share of 31.9% of the regenerative medicine market.
- Conditions that affect the joints and certain connective tissues are known as musculoskeletal conditions.
- The high incidence of bone-related injuries and the rising prevalence of musculoskeletal disease are increasing the demand for regenerative medicine.
- According to the Australian Institute of Health and Welfare, around 7.3 million people (29%) in Australia are estimated to be living with chronic musculoskeletal conditions.
- Additionally, the increasing preference for regenerative medicine over surgery for muscle strain injuries in athletes and partial tendon tears is further contributing to the significant market share of this segment.
By End User
- The Hospital & Clinics Segment to Dominate the Regenerative Medicine Market
- The hospitals & clinics segment is expected to account for the larger share of the regenerative medicine market.
- This segment’s large market share can be attributed to the rising number of patient visits to hospitals, the growing number of hospitals, and the availability of advanced technological resources within these healthcare facilities.
- Additionally, funding is often provided to hospitals & clinics to establish dedicated regenerative medicine facilities.
- For instance, in October 2022, California's stem cell agency granted $8 million to Cedars-Sinai (U.S.), a non-profit teaching hospital and multi-specialty academic health science center.
- This grant aims to establish an Alpha Stem Cell Clinic, enhancing patient access to stem cell therapy.
Geographic analysis
North America
Largest shareIn 2024, North America is expected to account for the largest share of the 41.8% of regenerative medicine market. North America’s significant market share can be attributed to the increasing prevalence of target diseases such as cancer and cardiovascular diseases, growing funding for the development of regenerative medicine, the presence of key market players in the region, and the rising number of clinical trials. According to the Alliance for Regenerative Medicine (U.S.), an international organization for regenerative medicine, North America witnessed a notable increase in the number of clinical trials, reaching 394 trials during the third quarter of 2023 from 339 trials in the fourth quarter of 2022. Similarly, the number of developers engaged in cell therapy manufacturing in North America increased from 272 to 435 during the same period. This surge in clinical trials and the involvement of key players in the development of regenerative medicine contribute to North America’s significant market share.
Asia-Pacific
Fastest growthHowever, the market in Asia-Pacific is projected to register the highest CAGR of 25.0% during the forecast period. The growth of this regional market is attributed to the rising prevalence of target diseases, the growing adoption of stem cell technology, supportive government policies promoting the development of regenerative medicine, and increased funding and research and development (R&D) initiatives in this field. According to the Alliance for Regenerative Medicine (U.S.), investment in regenerative medicine in the Asia-Pacific region surged to $2.1 billion in the fourth quarter of 2023, up from $0.9 billion in the third quarter of the same year.
Competitive landscape
- May 2024
Bristol-Myers Squibb Company (U.S.) received approval from the U.S. FDA for Breyanzi, a CAR T-cell therapy used to treat relapsed or refractory mantle cell lymphoma (MCL) and refractory follicular lymphoma in adult patients.
- April 2024
AbbVie Inc. partnered with REGENXBIO Inc. (U.S.) to develop ABBV-RGX-314, a gene therapy for retinal diseases, specifically neovascular age-related macular degeneration and diabetic retinopathy.
- January 2024
Smith & Nephew plc (U.K.) acquired CartiHeal Ltd. (Israel), a company that develops Agili-C, an innovative sports medicine technology designed for cartilage regeneration in the knee.
- May 2023
Integra LifeSciences Holdings Corporation (U.S.) established a new Center of Innovation and Learning aimed at advancing regenerative technologies to meet critical clinical needs.
- Novartis AG · Switzerland
- Biogen Inc. (U.S.)
- Kite Pharma, Inc. (U.S.)
- Spark Therapeutics, Inc. (U.S.)
- Integra LifeSciences Corporation (U.S.)
- Sarepta Therapeutics, Inc. (U.S.)
- Takeda Pharmaceutical Company Limited · Japan
- Amgen Inc. (U.S.)
- CORESTEMCHEMON Inc. · South Korea
- Smith & Nephew plc · England
- Vertex Pharmaceuticals Incorporated (U.S.)
- CSL Behring, LLC (U.S.)
- Janssen Global Services, LLC (U.S.)
- Medtronic plc · Ireland
- AbbVie Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Ferring Pharmaceuticals A/S · Sweden
- Pfizer Inc. (U.S.)
- Vericel Corporation (U.S.)
Frequently asked questions
The regenerative medicine market report analyzes various segments of regenerative medicine, such as product, application, and end user, at the regional and country levels. It also provides insights on factors impacting market growth, regulatory analysis, investment and funding scenarios, pipeline analysis, and Porter’s five forces analysis.
Cite this report
Meticulous Research. (2025). Regenerative Medicine Market - Global Opportunity Analysis And Industry Forecast (2025-2032) (Report No. MRHC - 1041181). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/regenerative-medicine-market-5864